Compare Bristol-Myers Squibb Co (BMY) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Delta Air Lines, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.75 (market cap $129.94B), while Delta Air Lines, Inc. trades at $89.67 (market cap $59.46B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.2× Delta Air Lines, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | DAL | |
|---|---|---|
Market Cap | $129.94B | $59.46B |
Sector | Health | Industrials |
52-Week High | $65.89 | $93.66 |
52-Week Low | $42.60 | $55.65 |
Enterprise Value | $163.92B | $74.77B |
Dividend Yield | 3.96% | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Delta Air Lines (DAL) trades at $89.70, up 0.55% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $1.56 versus $1.49 expected, maintaining a consistent earnings beat streak. Revenue growth has accelerated from $50.6B in 2022 to $63.4B in 2025, while net income improved to $5.0B. Analyst consensus remains overwhelmingly positive with 82% buy ratings and a $108.27 price target representing 21% upside potential.
DAL presents compelling value with attractive valuation multiples (P/E 14.99, P/S 0.87) and strong profitability metrics (ROE 20.12%). Key risks include fuel cost volatility and competitive pressure, but the company's premium travel positioning and American Express partnership provide competitive advantages. The technical setup suggests continued upward momentum with support at $88-90 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
